Cortechs.ai has acquired CT imaging technology from medical imaging software firm ZepMed.
The acquisition includes ZepMed’s Class II U.S. Food and Drug Administration (FDA)-cleared AI-powered NeuroAlign CT software. NeuroAlign CT automates segmentation, alignment, and reformatting of head CT scans to improve diagnostic accuracy and streamline radiology workflows, allowing clinicians to identify subtle changes in brain anatomy.
Cortechs.ai develops and markets imaging software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. The firm’s offerings include NeuroQuant, NeuroQuant MS, NeuroQuant Brain Tumor, and OnQ Prostate software.
The ZepMed acquisition will expand Cortechs.ai’s neuroimaging portfolio, the San Diego-based firm said.
